TY - JOUR
T1 - Targeting Src in endometriosis-associated ovarian cancer
AU - Manek, R.
AU - Pakzamir, E.
AU - Mhawech-Fauceglia, P.
AU - Pejovic, T.
AU - Sowter, H.
AU - Gayther, S. A.
AU - Lawrenson, K.
N1 - Funding Information:
We would like to thank Lillian Young at the USC Immunohistochemistry core for immunohistochemistry services, and the patients who kindly donated the tissues used in this study. The project described was performed within the Norris Cancer Centre at USC, which is supported in part by award number P30CA014089 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. KL is supported by a K99/R00 award from the National Cancer Institute (grant number 1K99CA184415-01).
Publisher Copyright:
© 2016, The Author(s).
PY - 2016/8/1
Y1 - 2016/8/1
N2 - The SRC proto-oncogene is commonly overexpressed or activated during cancer development. Src family kinase inhibitors are approved for the treatment of certain leukemias, and are in clinical trials for the treatment of solid tumors. Src signaling is activated in endometriosis, a precursor of clear cell and endometrioid subtypes of epithelial ovarian cancers (OCs). We examined the expression of phosphorylated Src (Src-pY416) in 381 primary OC tissues. Thirty-six percent of OCs expressed Src-pY416. Src-pY416 expression was most common in endometriosis-associated OCs (EAOCs) (P=0.011), particularly in clear cell OCs where 58.5% of cases expressed Src-pY416. Src-pY416 expression was associated with shorter overall survival (log rank P=0.002). In vitro inhibition of Src signaling using 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2) resulted in reduced anchorage-independent and -dependent growth, and in three-dimensional cell culture models PP2 disrupted aggregate formation in Src-pY416-positive but not in Src-pY416-negative cell lines. These data suggest that targeting active Src signaling could be a novel therapeutic opportunity for EAOCs, and support the further pre-clinical investigation of Src family kinase inhibitors for treating OCs expressing Src-pY416.
AB - The SRC proto-oncogene is commonly overexpressed or activated during cancer development. Src family kinase inhibitors are approved for the treatment of certain leukemias, and are in clinical trials for the treatment of solid tumors. Src signaling is activated in endometriosis, a precursor of clear cell and endometrioid subtypes of epithelial ovarian cancers (OCs). We examined the expression of phosphorylated Src (Src-pY416) in 381 primary OC tissues. Thirty-six percent of OCs expressed Src-pY416. Src-pY416 expression was most common in endometriosis-associated OCs (EAOCs) (P=0.011), particularly in clear cell OCs where 58.5% of cases expressed Src-pY416. Src-pY416 expression was associated with shorter overall survival (log rank P=0.002). In vitro inhibition of Src signaling using 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2) resulted in reduced anchorage-independent and -dependent growth, and in three-dimensional cell culture models PP2 disrupted aggregate formation in Src-pY416-positive but not in Src-pY416-negative cell lines. These data suggest that targeting active Src signaling could be a novel therapeutic opportunity for EAOCs, and support the further pre-clinical investigation of Src family kinase inhibitors for treating OCs expressing Src-pY416.
UR - http://www.scopus.com/inward/record.url?scp=85014093692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014093692&partnerID=8YFLogxK
U2 - 10.1038/oncsis.2016.54
DO - 10.1038/oncsis.2016.54
M3 - Article
AN - SCOPUS:85014093692
VL - 5
SP - e251
JO - Oncogenesis
JF - Oncogenesis
SN - 2157-9024
IS - 8
ER -